we aim :
* To evaluate how frailty influences acute management decisions (invasive vs conservative strategy) in ACS patients and whether it independently affects short-term outcomes. * To determine whether adding frailty assessment to existing ACS risk prediction models improves the prediction of 30-day mortality and major adverse cardiovascular events (MACE) in elderly ACS patients.
Elderly: Age ≥65 years .
STEMI/NSTEMI (ESC/ACC criteria)
Presentation <24h of symptom onset
Terminal illness (life expectancy <1 month)
Severe dementia precluding assessment
Declined consent
The study population consists of patients aged ≥65 years presenting with STEMI or NSTEMI within 24 hours of symptom onset, excluding those with terminal illness, severe dementia, or refusal of consent.
Cohort
Prospective
Not listed
30-day Major Adverse Cardiovascular Events (MACE)
Composite outcome including cardiovascular death, non-fatal myocardial infarction, stroke, or urgent revascularization, stratified by frailty status.
All-cause mortality
Mortality occurring during index hospitalization
Acute Kidney Injury (AKI)
AKI defined according to KDIGO criteria (increase in serum creatinine ≥0.3 mg/dL within 48 hours or ≥1.5 times baseline within 7 days).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
